Citizens are safe: Maharashtra FDA says no Coldrif syrup supplied in the State

On Sunday, October 5, 2025, after the reports of Child Deaths in Mahashtra Food and Drug Administration (FDA), Madhya Pradesh and Rajasthan, an urgent consultancy requesting an immediate suspension of the sale, distribution and use of the Coldrif syrup allegedly linked to the product.

The affected party, Coldrif syrup (phenylefrin hydrochloride, chlornamine maleat), SR-13, Sunguvarchathiram, Kancheepuram region, Tamil Nadu-based Sresan Pharma were produced in May 2025. It is set to end in April 2027. Laboratory analysis has revealed the presence of diethylene glycol (value), a toxic chemical that is common in industrial products such as antifreeze. Deg intake can cause renal failure and are linked to multiple deaths.

While talking HinduFDA drug controller Dr. Gahane, “Our state and citizens are safe. Tamil Nadu’daki drug control officials to watch the distribution of the party in Maharashtra, and Maharashtra’da Maharashtra’da whether it was difficult to come together, the cough for the safety of the cough.

The FDA instructed all pharmacies, hospitals, wholesalers and licenseers to immediately stop the processing of the party and inform local drug control officials. Citizens can also report the syrup with the number 1800222365, jchq.fda-h@nic.in e-mail or mobile 98928322289.

Drug Inspectors and Deputy Commissioner were deployed to warn their market stakeholders and to freeze the remaining stocks. Central Drugs Standard Control Organization (CDSCO) is expected to move tightly against the manufacturer and asked Tamil Nadu’s FDA to start a trial.

The public warning is also instructed to stop the sale/distribution/use of the Coldrif syrup immediately to the entire licensee and the public. The use of SR-13 and local drug control authorities were instructed to report it without delay.

The incident triggered the answers in several states. Madhya Pradesh brought a full prohibition for the syrup after the death of more than one child in Chhindwara. Rajasthan suspended the state pharmaceutical controller and stopped the distribution of all drugs from another manufacturer Kaysons Pharma, while a specialist committee to investigate.

The Ministry of Health of the Union also suggested that cough and cold drugs should not be prescribed to children under two years of age and proposed to guide health departments in all states and union regions.